XTNT Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of 0.18% compared to Xtant Medical Holdings's net margin of -0.77%. Xtant Medical Holdings's return on equity of -26.62% beat InfuSystems Holdings's return on equity of 5.82%.

Xtant Medical Holdings has a consensus price target of $1.75, signalling upside risk potential of 182.3%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.00 which suggests that it could grow by 154.55%. Given that Xtant Medical Holdings has higher upside potential than InfuSystems Holdings, analysts believe Xtant Medical Holdings is more attractive than InfuSystems Holdings.

Xtant Medical Holdings has a beta of -0.139, which suggesting that the stock is 113.918% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.813, suggesting its more volatile than the S&P 500 by 81.31%.

Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Xtant Medical Holdings quarterly revenues are $32.9M, which are smaller than InfuSystems Holdings quarterly revenues of $34.7M. Xtant Medical Holdings's net income of $58K is higher than InfuSystems Holdings's net income of -$267K. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 39.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.69x versus 0.86x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of 0.18% compared to Xtant Medical Holdings's net margin of -126.59%. Xtant Medical Holdings's return on equity of -26.62% beat Retractable Technologies's return on equity of -26.39%.

Xtant Medical Holdings has a consensus price target of $1.75, signalling upside risk potential of 182.3%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Xtant Medical Holdings has higher upside potential than Retractable Technologies, analysts believe Xtant Medical Holdings is more attractive than Retractable Technologies.

Xtant Medical Holdings has a beta of -0.139, which suggesting that the stock is 113.918% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.357, suggesting its more volatile than the S&P 500 by 35.696%.

Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Xtant Medical Holdings quarterly revenues are $32.9M, which are larger than Retractable Technologies quarterly revenues of $8.3M. Xtant Medical Holdings's net income of $58K is higher than Retractable Technologies's net income of -$10.5M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.69x versus 0.60x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of 0.18% compared to Xtant Medical Holdings's net margin of -2201.34%. Xtant Medical Holdings's return on equity of -26.62% beat VolitionRX's return on equity of --.

Xtant Medical Holdings has a consensus price target of $1.75, signalling upside risk potential of 182.3%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 355.11%. Given that VolitionRX has higher upside potential than Xtant Medical Holdings, analysts believe VolitionRX is more attractive than Xtant Medical Holdings.

Xtant Medical Holdings has a beta of -0.139, which suggesting that the stock is 113.918% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Xtant Medical Holdings quarterly revenues are $32.9M, which are larger than VolitionRX quarterly revenues of $246.4K. Xtant Medical Holdings's net income of $58K is higher than VolitionRX's net income of -$5.4M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.69x versus 44.53x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of 0.18% compared to Xtant Medical Holdings's net margin of -2828.67%. Xtant Medical Holdings's return on equity of -26.62% beat Catheter Precision's return on equity of -137.84%.

Xtant Medical Holdings has a consensus price target of $1.75, signalling upside risk potential of 182.3%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 788.89%. Given that Catheter Precision has higher upside potential than Xtant Medical Holdings, analysts believe Catheter Precision is more attractive than Xtant Medical Holdings.

Xtant Medical Holdings has a beta of -0.139, which suggesting that the stock is 113.918% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

Xtant Medical Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xtant Medical Holdings pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Xtant Medical Holdings quarterly revenues are $32.9M, which are larger than Catheter Precision quarterly revenues of $143K. Xtant Medical Holdings's net income of $58K is higher than Catheter Precision's net income of -$4M. Notably, Xtant Medical Holdings's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xtant Medical Holdings is 0.69x versus 2.58x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.